ResearcherLithuanian University of Health SciencesActive in the last 2 years
Darius Stukas
Matched on ORCID iD 0000-0003-2059-9164; OpenAlex author ID A5078824147. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 5
- Circulating cell-free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non-malignant conditions First author DOI 10.1007/s00423-026-04267-0↗
- Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. Co-author DOI 10.1016/j.bcp.2025.116798↗
- Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2025.1655258↗
- Association between AHR Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blo… Co-author DOI 10.3390/cancers15184639↗
- Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway. Co-author DOI 10.3390/ijms241713155↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Žilvinas Dambrauskas · 5 shared papers, 2023–2026 · strength 1.08
- Paper Circulating cell-free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non-malignant conditions DOI 10.1007/s00423-026-04267-0↗
- Paper Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. DOI 10.1016/j.bcp.2025.116798↗
- Paper Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. DOI 10.3389/fimmu.2025.1655258↗
- Arenida Bartkevičienė · 5 shared papers, 2023–2026 · strength 1.08
- Paper Circulating cell-free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non-malignant conditions DOI 10.1007/s00423-026-04267-0↗
- Paper Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. DOI 10.1016/j.bcp.2025.116798↗
- Paper Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. DOI 10.3389/fimmu.2025.1655258↗
- Antanas Gulbinas · 4 shared papers, 2023–2025 · strength 0.79
- Paper Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. DOI 10.1016/j.bcp.2025.116798↗
- Paper Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. DOI 10.3389/fimmu.2025.1655258↗
- Paper Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway. DOI 10.3390/ijms241713155↗
- Romualdas Riauka · 1 shared paper, 2026 · strength 0.29
- Giedrius Barauskas · 1 shared paper, 2026 · strength 0.29
- Povilas Ignatavičius · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.